The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Guidelines often Based on Weak Evidence

Rheumatology Guidelines often Based on Weak Evidence

November 29, 2017 • By Will Boggs MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Most recent clinical practice guidelines (CPGs) from the American College of Rheumatology (ACR) are based on expert opinion and lack A-level evidence in support of their recommendations, researchers report.

You Might Also Like
  • Evidence-Based Practice: Making it a Reality
  • Do Osteoporosis Screening Guidelines Meet Patient Needs?
  • The RISE Registry Delivers Practice-Based Evidence to Rheumatologists
Also By This Author
  • Persistent Pain Merits Better Access to Psychosocial Care, Group Says

“I’d like to highlight not just for providers but also for patients and policymakers that, even though we in the United States are spending about 18% of our GDP on health care, many of our guideline recommendations are only level C,” Dr. John B. Wong from Tufts Medical Center, in Boston, told Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Wong’s team assessed eight publicly available rheumatology CPGs by evaluating the level (quality) of the evidence base and the class (strength) of the recommendations. They reported their findings online November 27 in JAMA Internal Medicine.

Of 403 recommendations evaluated, more than half were classified as level C (expert opinion, case studies, or standard of care); only one-fourth were level A (multiple randomized clinical trials or meta-analyses); and one-fifth were level B (single RCT or nonrandomized studies).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The proportion of recommendations supported by A-level evidence ranged from 2% for juvenile idiopathic arthritis and 10% for polymyalgia rheumatica to 35% for glucocorticoid-induced osteoporosis and 58% for osteoarthritis.

A median 10% of recommendations specified both level of evidence A and strength class I (benefit much greater than harm), 6% specified level B and class I, and 8% specified level C and class I.

The combination of C-level evidence and class II strength (benefit greater than or equal to harm) was the most common at a median of 30% across guidelines (50% of the rheumatoid arthritis recommendations).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Our findings that the minority of guideline recommendations have level of evidence A (multiple randomized controlled trials) supporting them are consistent with similar analyses of other subspecialty guidelines, including cardiology, infectious diseases and nephrology,” Dr. Wong said. “Given that rheumatoid arthritis causes substantial morbidity, mortality, and resource consumption, it was most surprising that nearly 70% of the 35 rheumatoid arthritis recommendations were level of evidence C.”

Not all recommendations require level A evidence, e.g., it would be unnecessary to perform a randomized controlled trial of wearing a parachute when jumping out of a plane, so those level I recommendations even in the absence of level A evidence should be considered while recognizing that the evidence supporting them is not of the topmost quality,” he said.

“As our reimbursement system appears to be headed toward value-based performance, it is those level A evidence class I strength recommendations that will or could become performance or quality improvement measures, particularly if a performance gap has been demonstrated in practice,” Dr. Wong said.

Pages: 1 2 | Single Page

Filed Under: Practice Management Tagged With: A-level evidence, American College of Rheumatology (ACR), clinical practice guidelines (CPGs), Dr. John B. Wong, expert opinion

You Might Also Like:
  • Evidence-Based Practice: Making it a Reality
  • Do Osteoporosis Screening Guidelines Meet Patient Needs?
  • The RISE Registry Delivers Practice-Based Evidence to Rheumatologists
  • Living with RA: Study Examines the Value of Patient Involvement in Creating Clinical Practice Guidelines

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)